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To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and pharmacokinetics of topotecan administered as a 30-
min intravenous (i.v.) infusion over 5 days in combination with a 1-h i.v. infusion of ifosfamide (IF) for 3 consecutive days every 3
weeks. Patients with advanced malignancies refractory to standard therapy were entered into the study. The starting dose of
topotecan was 0.4mgm
 2day
 1 5 days. Ifosfamide was administered at a fixed dose of 1.2gm
 2day
 1 3 days. In all, 36 patients
received 144 treatment courses. Owing to toxicities, the schedule of topotecan administration was reduced from 5 to 3 days. The
MTD was reached at topotecan 1.2mgm
 2day
 1 3 days with IF 1.2gm
 2day
 1 3 days. Haematological toxicities were dose
limiting. Neutropenia was the major toxicity. Thrombocytopenia and anaemia were rare. Nonhaematological toxicities were relatively
mild. Partial responses were documented in three patients with ovarian cancer dosed below the MTD. Topotecan and IF did not
appear to interact pharmacokinetically. The relationships between the exposure to topotecan lactone and total topotecan, and the
decrease in absolute neutrophil count and the decrease in thrombocytes, were described with sigmoidal–Emax models. The
combination of 1.0mgm
 2day
 1 topotecan administered as a 30-min i.v. infusion daily times three with 1.2gm
 2day
 1 IF
administered as a 1-h i.v. infusion daily times three every 3 weeks was feasible. However, the combination schedule of topotecan and
IF did result in considerable haematological toxicity and in conjunction with previously reported pronounced nonhaematological
toxicities and treatment related deaths, it may be concluded that this is not a favourable combination.
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Topotecan (Hycamtin
s) is a semisynthetic analogue of the
alkaloid camptothecin that acts as a specific inhibitor of the
nuclear enzyme topoisomerase-I (Herben et al, 1996). Inhibition of
this enzyme results in lethal DNA damage during transcription and
replication. The E-ring lactone in the basic structure of topotecan
is considered essential for the interaction with topoisomerase-I
(Herben et al, 1996) In vivo, rapid conversion of the active lactone
to the inactive carboxylate form occurs. Topotecan is indicated for
second-line treatment of advanced ovarian cancer or refractory
small-cell lung cancer, and has demonstrated antitumour activity
in non-small-cell lung cancer, prostate cancer, and colorectal
cancer (Herben et al, 1996).
Ifosfamide (IF) (Holoxan
s, Ifex
s) is an alkylating agent, which
is indicated as third-line agent in the treatment of germ cell
testicular cancer in combination with other chemotherapeutic
agents. It is also used to treat cancers of the head and neck, breast,
cervix, ovaries, soft tissue sarcoma, Ewing’s sarcoma, osteosarco-
ma, both Hodgkin’s and non-Hodgkin’s lymphomas, non-small-
cell lung cancer, acute lymphocytic leukaemia, and neuroblastoma
(Kerbusch et al, 2001a). Ifosfamide is a prodrug, which needs to
undergo activation by cytochrome P450-3A4 (CYP3A4) to 4-
hydroxyifosfamide (4OHIF). Intracellular spontaneous decompo-
sition of 4OHIF yields the ultimate alkylating metabolite ifosfor-
amide mustard (IFM). Ifosfamide is deactivated to the
noncytotoxic metabolites 2- and 3-dechloroethylifosfamide
(2DCE and 3DCE), yielding an equimolar amount of neurotoxic
chloroacetaldehyde (Cerny and Ku ¨pfer, 1992). Ifosfamide metabo-
lism is autoinducible (Kerbusch et al, 2000b).
In a phase I study with the combination topotecan and
cyclophosphamide, an isomer of IF, synergism was suggested
between alkylating agents and topoisomerase-I inhibitors (Murren
et al, 1997). It was proposed that DNA alkylation triggers DNA
repair mechanisms, which may depend on topoisomerase-I.
Ifosfamide was chosen as representative alkylator because it is
associated with less haematological toxicity than cyclophospha-
mide (Kerbusch et al, 2001a).
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lThese data led us to evaluate a chemotherapeutic regimen of
topotecan in combination with IF. Aims of this phase I trial were to
determine the maximum-tolerated dose (MTD), dose-limiting
toxicity (DLT), and the safety profile of the combination of daily
30-min infusions of topotecan on days 1–5 followed by 1.2gm
 2
IF administered as a 1-h infusion daily on days 1–3 every 3 weeks
in patients with advanced malignancies. Secondary aims were the
assessment of the pharmacokinetics of topotecan and IF and its
main metabolites when given in combination and documentation
of any antitumour activity of this regimen.
PATIENTS AND METHODS
Eligibility criteria
The eligibility criteria were histologically confirmed metastatic or
locally advanced cancer, no proven benefit of existing anticancer
therapy, age between 18 and 75 years, World Health Organisation
(WHO, 1979) performance status p2, adequate bone marrow
function (white blood cells (WBC) X3.5 10
9l
 1, granulocytes
X1.5 10
9l
 1, platelets X100 10
9l
 1, haemoglobin
X6mmoll
 1), adequate hepatic function (serum bilirubin
p20mmoll
 1, alanine-aminotransferase (ALAT), aspartate-amino-
transferase (ASAT), and alkaline phosphatase (AP) p2 the
upper limit of the reference range or p5 the upper limit of the
reference range if the elevation was directly contributed to the
presence of metastatic disease), adequate renal function (serum
creatinine p120mmoll
 1 or creatinine clearance (CL)
X60mlmin
 1), evaluable disease, and a life expectancy X3
months. The exclusion criteria were breast feeding, pregnancy or
inadequate contraceptive protection, drug, medication or alcohol
abuse, treatment with an investigational drug p1 month prior to
the study entry, surgery, radiotherapy (except for analgesic
indications) or chemotherapy (mitomycin C or nitrosoureas
p1.5) p1 month prior to the study entry, other diseases altering
procedures of the trial, history of seizures or central nervous
system disorders, severe intercurrent infection, serious uncon-
trolled concurrent medical or psychiatric disease, known hyper-
sensitivity to IF or topotecan, and prior treatment with IF or
topotecan. The study protocol was approved by the Ethics Review
Boards of the Antoni van Leeuwenhoek Hospital/The Netherlands
Cancer Institute and University Medical Center Utrecht. The trial
was conducted in these two centres according to Good Clinical
Practice and the current edition of the Declaration of Helsinki.
Written informed consent was obtained from all patients entering
the study.
Toxicity and response evaluation
Pretreatment evaluation included a complete medical history and
complete physical examination. Before each course, blood
chemistry and haematological profiles were checked, and urina-
lysis was performed. Complete blood cell counts and blood
chemistry were repeated weekly. Electrocardiograms and tumour
measurements (by physical examination, chest X-ray, other
radiological investigations or ultrasound) were performed every
other cycle. All toxicities were graded according to the National
Cancer Institute Common Toxicity Criteria (NCI-CTC, 1998).
Dose-limiting toxicities were defined as any of the following events
occurring during the first treatment cycle and attributable to either
IF or topotecan: (1) grade IV neutropenia lasting X7 days or of
any duration associated with severe systemic infection requiring
parental treatment; (2) febrile neutropenia; (3) grade III or IV
thrombocytopenia with or without haemorrhagic complications;
or (4) grade III or IV nonhaematological toxicity excluding nausea/
vomiting responsive to treatment, anorexia, and alopecia. The
MTD was defined as the dose at which Xtwo out of three or Xtwo
out of six patients experienced DLT. The next lower dose level
below the MTD was the recommended dose for phase II studies.
Responses were determined according to the WHO criteria (WHO,
1979).
Dose escalation
Doses of topotecan were escalated during the study. Starting dose
was 0.4mgm
 2day
 1 topotecan for 5 days by means of a 30-min
infusion. Escalation was planned with 0.2mgm
 2day
 1 incre-
ments per dose level. Ifosfamide was administered at a fixed dose
of 1.2gm
 2day
 1 for 3 days by means of a 1-h infusion.
Ifosfamide was administered directly after the topotecan infusion.
Upon identification of the MTD, the protocol was amended to
reduce topotecan dosing from 5 to 3 days. Treatment cycles were
repeated every 21 days, provided patients had sufficiently
recovered from any drug-related toxicity associated with the
previous course (nonhaematological toxicity Xgrade I, alopecia
excluded, haemoglobin X6mmoll
 1 and return of blood cell
counts to X1.5 10
9l
 1 neutrophils and X100 10
9l
 1 platelets).
Dose modifications of both IF and topotecan were made if
poor subjective tolerance to treatment occurred. Neutrophils
o0.5 10
9l
 1 associated with temperature X38.51C or lasting
longer X7 days, neutrophils o1.0 10
9l
 1 lasting longer X21
days, platelets o50 10
9l
 1 or any nonhaematological toxicity
requiring a delay in treatment resulted in dose reduction
of 25% and platelets o25 10
9l
 1 resulted in dose reduction of
50%.
Drug administration
Topotecan (Hycamtin
s) was supplied by GlaxoSmithKline (Zeist,
The Netherlands) in vials containing topotecan HCl, equivalent to
5mg of free base. Inactive ingredients were 60mg mannitol and
25mg tartaric acid. The content of each vial was reconstituted with
2ml sterile water for injection. The appropriate dosage of the drug
was diluted in 50ml of 0.9% NaCl solution. Topotecan was
administered through a peripheral venous access device using a
syringe pump. Ifosfamide (Holoxan
s) was supplied by Asta
Medica BV (Diemen, The Netherlands) in vials containing 0.5, 1 or
2g without excipients. Ifosfamide was diluted in 0.9% NaCl to
approximately 1l and administered through a peripheral venous
access device using an ambulatory infusion pump. Supportive care
consisted of 5HT3-antagonists, corticosteroids and mesna. Mesna
was administered as protective agent for IF-induced bladder
toxicity. The bolus dose of mesna was 50% of the dose of IF, which
was followed by continuous intravenous (i.v.) infusion of mesna at
a dose of 50% of the dose of IF during and 8h after the IF infusion.
The protocol did not allow the use of bone marrow granulocyte
colony-stimulating factors (G-CSF).
Pharmacokinetic sampling
Pharmacokinetic studies were performed for topotecan (total and
lactone form) and IF and metabolites (2- and 3DCE, 4OHIF, and
IFM) during the first two treatment courses. Intravenous samples
were drawn from an indwelling intravenous cannula placed in the
arm contralateral to the arm receiving chemotherapy prior to the
topotecan infusion and at the following time points after the start
of the topotecan infusion: 15, 30 (prior to the end of the topotecan
infusion), 60 and 90min (prior to the end of the IF infusion), and
2, 3, 4.5, 7.5, 11, and 24h (prior to the start of the following
topotecan infusion). Pharmacokinetic sampling was executed
according to this schedule on days 1 and 3 of cycle 1 and day 1
of cycle 2. Blood samples were immediately placed on icewater.
The plasma was immediately separated by centrifugation at 1000g
for 5min at 41C. For the analysis of topotecan lactone plasma
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lprotein precipitation was performed by adding 1ml plasma to 2ml
cold methanol ( 201C). The sample was mixed on a whirl mixer
for 10s and centrifuged for 3min at 1000g at 41C. The clear
supernatant was transferred to a polypropylene tube and
immediately stored at  701C pending analysis. Furthermore,
plasma was aliquoted in three 1-ml volumes. Two aliquots were
used for 4OHIF analysis after stabilisation with semicarbazide and
one aliquot was used for IFM analysis after stabilisation with
semicarbazide and sodium chloride. The remaining plasma was
aliquoted to two 0.5-ml volumes for the analysis of IF, 2DCE and
3DCE, and total topotecan. Urine was collected during the first
course for 96h after the start of the IF infusion and an aliquot was
analysed for IF, 2DCE and 3DCE. Both plasma and urine samples
were immediately stored at  701C, pending analysis. Total
topotecan (lactone plus carboxylate form) and the lactone form
were determined separately using a high-performance liquid
chromatographic (HPLC) system with fluorometric detection
(Rosing et al, 1995). Gas chromatography with selective nitro-
gen–phosphorous detection was used for the determination of IF,
2DCE and 3DCE, in urine and plasma (Kerbusch et al, 2000c). Two
separate HPLC methods were used for the determination of 4OHIF
and IFM concentrations (Kerbusch et al, 1998, 2000a).
Pharmacokinetic evaluation
The pharmacokinetics of lactone and total topotecan were
described with a two-compartment model, yielding CL (lh
 1),
volume of distribution of the central compartment (V, l), volume
of distribution at steady state (Vss, l) and intercompartmental CL
(Q,l h
 1). The pharmacokinetics of IF and its main metabolites
were described using an integrated nonlinear model with
autoinduction (Kerbusch et al, 2000b, 2001b,c). This model
described the pharmacokinetics of IF with an initial CL of IF
(CLinit,l h
 1) and a volume of distribution (Vifo, l), and
autoinduction with a first-order rate constant for enzyme
degradation/inactivation (Kenz,out,h
 1) and an IF concentration
at 50% of the maximum inhibition of enzyme degradation (IC50,
mM). The induction half-life of the enzyme (t1/2,enz, h) was
calculated by the ratio of ln(2) and Kenz,out. The pharmacokinetics
of the metabolites were described with a ratio of the fraction of IF
metabolised and the volume of distribution of that metabolite (Fm/
Vm¼F
*,l
 1), an elimination rate constant (K,h
 1) and a rate
constant (F
**) from 4OHIF to IFM (Kerbusch et al, 2001b). The
exposure to a compound was described by the area under the
plasma concentration–time curve (AUC). All pharmacokinetic
models were fitted to the data from the individuals using the
population pharmacokinetic program NONMEM (Non-linear
Mixed Effects Modelling, Version V) (Boeckman et al, 1994), with
first-order conditional estimation (FOCE). The residual or
intraindividual variability of the pharmacokinetics were described
separately with a combined proportional and additive term. The
interindividual variability (IIV) of each pharmacokinetic para-
meter was estimated using a proportional error model.
Pharmacokinetic–pharmacodynamic relationships
Relationships between the AUC of lactone and total topotecan and
myelosuppression were explored using scatter plots of the AUC vs
the percentage decrease in absolute neutrophil count (ANC) and
thrombocytes (THR). The percentage decrease was defined as:
%decrease ¼
baselinecount   nadircount
baselinecount
 100%
The data were fit to a sigmoidal maximum effect (Emax) model,
as described by the modified Hill equation (Holford and
Sheiner, 1992):
%decrease ¼
ðEmax DEgÞ
ðDEg
50 þ DEgÞ
where Emax denotes the maximal effect that can be elicited, DE
is a measure of drug exposure (ie AUC), DE50 represents the
drug exposure associated with 50% of Emax and g is the
Hill coefficient, which describes the sigmoidicity of the curve.
Since the percentage decrease could not exceed 100%, Emax was
fixed to 100. Separate exposure–response models were described
for total and lactone form of topotecan using NONMEM with
FOCE and interaction. The residual variability (RV) was described
with an additive term. The interoccasion variability (IOV) of
AUC50 was estimated using a proportional error model. In
addition, combined exposure–effect models (additive) were
explored of the topotecan plus IF–myelosupression relationship.
Additivity was modelled by assuming separate terms (Hill
equations) for each active moiety (A and B) plus a scaling for
relative potency (RP):
%decrease ¼ðRPÞ 
ðEmax AUC
gA
A Þ
ðAUC
gA
50;A þ AUC
gA
A Þ
þð 1   RPÞ 
ðEmax AUC
gB
B Þ
ðAUC
gB
50;B þ AUC
gB
B Þ
The active moieties (A and B) tested were topotecan lactone/total
and 4OHIF.
RESULTS
Patients
At the end of the study, 36 patients received 144 courses at seven
dose levels. Patient characteristics are listed in Table 1. The
medium number of courses administered per patient was 3 (range
1–10). In four patients only one treatment course was adminis-
tered because of rapidly progressive disease. Two of these patients
developed an ileus, one with a septic shock and one with lethal
intestinal bleeding. This was considered disease related. Two
courses were delayed in one patient and treatment discontinued in
another at dose level 5 (1.0mgm
 2day
 1 3), due to the
occurrence of an ileus.
Dose escalation
All patients were assessable for toxicity during the first treatment
course. Doses of topotecan were escalated according to the scheme
depicted in Table 2. Myelosuppression was the DLT for the
combination of topotecan and IF in this schedule (Table 3). To
investigate further dose-intensification topotecan dosing was
reduced from 5 to 3 days, yielding a total dose at level 3 (1.8mg
topotecan) similar to level 1 (2.0mg topotecan). At dose level 3, six
patients were included, because the first three only had five
evaluable courses due to progressive disease. At dose level 6, two
out of eight patients experienced DLT meeting the MTD criteria of
Xtwo out of six patients, and it was concluded that the MTD was
achieved at dose level 6 (topotecan 1.2mgm
 2day
 1 3 and IF
1.2gm
 2day
 1 3). Four additional patients were entered at dose
level 5 at the recommended dose.
Haematological toxicity
Myelosuppression was the principal toxicity. Table 3 lists the
frequency of the grade III and IV haematological toxicities during
treatment course 1 and during all courses. A total of 144 courses
were evaluated, involving all 36 patients. Overall, grade III
thrombocytopenia (3%) and grade III (6%) and IV (1%) anaemia
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lwere rare. The single observed grade IV anaemia was considered
not related to the study drugs. Neutropenia grades III and IV
occurred in 29 (20%) and 59 (41%) of all courses, respectively.
Neutropenic fever was observed in seven (5%) courses. In all,
23 (16%) of all treatment courses were delayed for 1 week.
Three patients had unresolved neutropenia at day 21, one patient
had two episodes of ileus, one patient had two episodes of
severe ascitis, and three courses were postponed upon patients’
request. Dose reductions due to neutropenia were performed in
18 (13%) of 144 treatment courses involving nine patients. At
dose level 2 (0.6mgm
 2day
 1 5), one patient received two
courses at 75% of the intended dose and another patient received
four courses with topotecan for 3 days instead of 5 days. At
dose level 3, one patient received one course at 75% of the
intended topotecan dose. At dose level 6, one patient developed
grade IV neutropenia with fever, which was resolved before the
start of the second course. However, the fever reoccurred during
the second day of the second course. This prompted an early
infusion discontinuation after the first day of the second course.
One patient at dose level 6 experienced grade III thrombocytope-
nia and grade IV neutropenia with neutropenic fever and
another patient at dose level 6 and two at dose level 7 experienced
grade IV neutropenia 47 days. Consequently, the dose of
topotecan and IF was reduced by 25% in all subsequent courses
in these patients.
There was no indication of cumulative myelosuppression on
repeated dosing, evidenced by similar or less prominent haemo-
globin, neutrophil, and platelet nadirs in later courses compared
with the first course (Table 4). The neutrophil nadir typically
occurred between days 7 and 14 (median 10 days). Absolute
neutrophil counts at dose level 2 (dose intensity 3.0mgm
 2) were
comparable to dose levels 5 and 6 (dose intensities 3.0 and
3.6mgm
 2, respectively). A similar pattern was observed with the
haemoglobin and platelet levels of dose levels 2 and 6. Most
patients in the study received infusions of packed cells due to
anaemia.
Table 1 Patient characteristics
Characteristic Number %
Number of patients 36
Male/female 6/30
Age (years)
Median 57
Range 32–77
Performance status
01 2 3 3
12 0 5 6
24 1 1
Primary tumour site
Colon 2 6
Cervix 1 3
Melanoma 1 3
Ovarian 22 61
Gastric 2 6
Pancreas 1 3
Renal 1 3
Oropharynx 1 3
Non-small-cell lung cancer 4 11
Urogenital 1 3
Prior palliative chemotherapy 34 94
Number of previous regimens
Median 1
Range 1–6
Prior radiotherapy 7 19
Table 2 Topotecan dose escalation
Dose level Number of patients DLT type and grade Topotecan dose Total topotecan dose (mgm
 2)
1 3 0.4mgm
 2day
 1 5 days 2.0
2 3 (DLT in one of three) T III, N IV, A IV, toxic death 0.6mgm
 2day
 1 5 days 3.0
1 2 0.4mgm
 2day
 1 5 days 2.0
3 6 0.6mgm
 2day
 1 3 days 1.8
4 3 0.8mgm
 2day
 1 3 days 2.4
5 3 1.0mgm
 2day
 1 3 days 3.0
6 6 (DLT in one of six) N IV, feverX7 days 1.2mgm
 2day
 1 3 days 3.6
7 4 (DLT in two of four) N IV, feverX7 days (both) 1.4mgm
 2day
 1 3 days 4.2
6 2 (DLT in one of two) N IV, feverX7 days 1.2mgm
 2day
 1 3 days 3.6
5 4 1.0mgm
 2day
 1 3 days 3.0
When level 7 resulted in DLT additional patients were recruited at level 6 and subsequently at level 5. The latter is the advised level for further studies. T¼thrombocytopenia;
N¼neutropenia; A¼anaemia; DLT¼dose-limiting toxicity.
Table 3 Haematological toxicities in 144 courses
Anaemia
a Neutropenia
a Thrombocytopenia
a
Dose
level Topotecan dose
Number of
patients
Number of
courses Grade III Grade IV Grade III Grade IV Grade III Grade IV
1 0.4mgm
 2 5 days 5 20 0 (0%)/1 (5%) 0 (0%)/0 (0%) 1 (20%)/1 (5%) 0 (0%)/2 (10%) 0 (0%)/0 (0%) 0 (0%)/0 (0%)
2 0.6mgm
 2 5 days 3 10 0 (0%)/0 (0%) 1 (33%)/1 (10%) 0 (0%)/0 (0%) 2 (67%)/4 (40%) 1 (33%)/1 (10%) 0 (0%)/0 (0%)
3 0.6mgm
 2 3 days 6 17 0 (0%)/0 (0%) 0 (0%)/0 (0%) 0 (0%)/6 (35%) 2 (33%)/4 (24%) 0 (0%)/0 (0%) 0 (0%)/0 (0%)
4 0.8mgm
 2 3 days 3 22 0 (0%)/1 (5%) 0 (0%)/0 (0%) 0 (0%)/6 (27%) 1 (33%)/7 (32%) 0 (0%)/0 (0%) 0 (0%)/0 (0%)
5 1.0mgm
 2 3 days 7 32 2 (29%)/4 (13%) 0 (0%)/0 (0%) 2 (29%)/8 (25%) 4 (57%)/9 (28%) 0 (0%)/0 (0%) 0 (0%)/0 (0%)
6 1.2mgm
 2 3 days 8 25 1 (13%)/2 (8%) 0 (0%)/0 (0%) 0 (0%)/4 (16%) 7 (88%)/19 (76%) 1 (13%)/2 (8%) 0 (0%)/0 (0%)
7 1.4mgm
 2 3 days 4 18 0 (0%)/0 (0%) 0 (0%)/0 (0%) 0 (0%)/4 (22%) 4 (100%)/14 (78%) 0 (0%)/1 (6%) 0 (0%)/0 (0%)
aNumber (percentage) of patients developing toxicity in the first course/number (percentage) of courses causing toxicity.
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Nonhaematological toxicities were relatively mild and not dose
related (Table 5). One patient (six courses) with peripheral
neuropathy grade I had pre-existing neuropathy due to cisplatin
pretreatment. In one patient, an episode of sensory neuropathy
grade II was suspected to be treatment related, but in another
patient an episode of grade III was considered not to be related,
because of confirmed CNS metastases. All toxicities, including
neuropathy, were reversible and rapidly vanished after therapy was
stopped.
Blood chemistry prior to treatment did not exceed reference
values. The median creatinine CL prior to treatment was
92mlmin
 1 and ranged between 48 and 148mlmin
 1; this was
unaltered prior to the second course. In one patient, increased
levels of AP, ASAT, and ALAT (946, 103, and 132U/l, respectively)
were observed after the first course. Later, this patient was found
to have an obstructed biliary tract due to tumour growth. Between
courses 1 and 2, a total of six and 10 patients had calcium and
magnesium levels below the reference values of 2.2 and
0.7mmoll
 1, respectively.
Pharmacokinetics
Total topotecan pharmacokinetic data were obtained in the first
course of 32 patients and in the second course of 17 patients,
respectively. Lactone topotecan pharmacokinetic data were
obtained in the first course of 16 patients and in the second
course of 15 patients. Typical plasma profiles of topotecan lactone
and total topotecan of a patient receiving 1.2mgm
 2day
 1
topotecan are displayed in Figure 1. The lactone form was the
predominant form during the infusion, but approximately 30min
after the end of the infusion the open-ring (carboxylate) form
concentrations exceeded lactone levels. The mean (7s.d.) lactone-
to-total topotecan ratio at the end of the infusion was 0.7470.10
(n¼23). After the end of the infusion, lactone curves exhibited a
biexponential decay. The population pharmacokinetic parameters
of topotecan lactone and total topotecan are listed in Table 6.
Variability between patients and between courses 1 and 2 was
modest. The relationship between the AUC of lactone and total
Table 4 Nadir blood counts in 144 courses
ANC ( 10
9l
 1) Haemoglobin (mmoll
 1) Platelets ( 10
9l
 1)
1st course All courses 1st course All courses 1st course All courses
Dose
level
Topotecan
dose
Number
of
patients
Number
of
courses
Median
(range)
Median
(range)
Median
(range)
Median
(range)
Median
(range)
Median
(range)
1 0.4mgm
 2 5 days 5 20 1.9 (0.7–3.5) 2.0 (0.4–3.5) 6.4 (5.4–7.1) 6.5 (4.4–7.1) 230 (99–403) 165 (99–445)
2 0.6mgm
 2 5 days 3 10 0.4 (0.2–1.3) 1.0 (0.2–2.4) 5.6 (3.4–5.7) 5.7 (3.4–6.6) 79 (25–231) 212 (25–282)
3 0.6mgm
 2 3 days 6 17 1.4 (0.1–3.7) 0.7 (0.04–4.0) 6.2 (5.9–7.0) 5.9 (5.0–7.3) 190 (125–283) 175 (78–283)
4 0.8mgm
 2 3 days 3 22 2.1 (0.3–3.5) 0.7 (0.1–3.5) 6.1 (5.7–7.5) 6.5 (4.7–7.5) 176 (129–230) 197 (129–279)
5 1.0mgm
 2 3 days 7 32 0.5 (0.1–1.1) 0.8 (0.1–2.3) 5.5 (4.0–6.8) 5.7 (4.0–7.1) 193 (115–269) 175 (110–514)
6 1.2mgm
 2 3 days 8 25 0.2 (0.02–2.1) 0.3 (0.02–2.1) 6.2 (4.9–7.0) 6.1 (4.8–7.1) 101 (44–201) 131 (37–419)
7 1.4mgm
 2 3 days 4 18 0.3 (0.05–0.3) 0.3 (0.05–0.6) 7.1 (5.3–7.8) 6.3 (5.2–7.8) 112 (66–237) 150 (38–279)
ANC¼absolute neutrophil count.
Table 5 Nonhaematological toxicity in 144 courses of 36 patients
Percentage of courses (number of patients) Percentage of courses (number of patients)
Toxicity Grade I Grade II Grade III Toxicity Grade I Grade II Grade III
Vomiting 24% (16) 10% (8) 1% (1) Peripheral neuropathy 14% (6) 2% (1)
Nausea 35% (23) 20% (14) 3% (4) Vertigo 3% (4)
Abdominal cramps 4% (5) 2% (2) Headache 5% (6) 2% (2)
Constipation 30% (23) 8% (9) 1% (2) Anxiety 5% (4)
Anorexia 2% (3) Pain 15% (9) 5% (6) 5% (5)
Diarrhoea 8% (10) 3% (3) 1% (1) Myalgia 4% (5) 1% (1)
Fatigue 15% (13) 17% (13) 2% (2) Dyspnoea 1% (2) 3% (3) 2% (3)
Fever 7% (8) 5% (5) 3% (4) Infection 3% (5) 4% (6)
Asthenia 6% (4) 4% (3) 2% (3) Cough 7% (7)
Alopecia 9% (9) 47% (26) Haemorrhage (urine) 1% (1)
0.001
02 4 4 87 2
0.01
0.1
1
10
100
Time (h)
T
o
p
o
t
e
c
a
n
 
c
o
n
c
.
 
(
n
M
)
Figure 1 A typical plasma concentration–time profile of total topotecan
(solid markers) and topotecan lactone (open markers) of a patient
receiving a 30-min administration of 1.2mgm
 2day
 1 topotecan for 3
consecutive days.
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ltopotecan with the absolute topotecan dose is represented in
Figure 2. Moderate IIV in exposure was observed.
Plasma concentration–time profiles of IF and its metabolites are
presented in Figure 3. A decrease in the elimination half-life of IF
was observed when comparing the monoexponential decays on
days 1 and 3, due to the autoinduction of the IF metabolism. This
effect was reset at the start of the next course. The population
pharmacokinetic parameters of IF and its metabolites are listed in
Table 7. The concentration–time data did not allow estimation of
IC50 and it was therefore fixed at 0.001mM, which was below the
lower limit of quantification. Fixing IC50 resulted in an adequate
description of the development of autoinduction of the IF
metabolism. Insufficient data were available to estimate the
elimination rate of the hydroxylated metabolite (K4OHIF), which
was therefore fixed to a value (73.8h
 1) obtained from a prior
analysis (Kerbusch et al, 2001b). Variability between patients in IF
pharmacokinetics was modest and somewhat larger for the
metabolites. The mean (7s.d.) urinary excretion of IF was
34.7712.1% of the administered dose with 17.8710.0% as
unchanged IF, 5.672.2% as 2DCE, and 11.273.8% as 3DCE.
Pharmacodynamics
The relationships between the AUC for the lactone and total
topotecan and the percentage decrease in neutrophils could
adequately be described by sigmoidal–Emax models (Figure 4).
Estimates for AUC50 and the Hill coefficient are presented in
Table 8. The individual estimates of the AUC50 between courses 1
and 2 decreased with 9 and 12%, respectively. However, this
difference in potency was not statistically significant (Po0.05),
because including a nonrandom course effect only resulted in a
Table 6 Pharmacokinetics of topotecan lactone and total topotecan (lactone and carboxylate form) with their s.e., IIV, IOV and RV
Topotecan lactone Total topotecan
Estimate (7s.e.) IIV IOV RV Estimate (7s.e.) IIV IOV RV
CL (lh
 1) 68.073.2 16% 9% 24.971.2 23% 12%
V (l) 29.571.2 22% — 16.673.5 45% —
Vss (l) 13377 16% — 80.072.8 17% —
Q (lh
 1) 66.372.3 4% — 129723 12% —
PE 15.9% 13.0%
AE (mm) 0.150 0.392
CL¼clearance, V¼volume of distribution of central compartment, Vss¼volume of distribution at steady state, Q¼intercompartmental clearance, PE¼proportional error,
AE¼additive error; s.e.¼standard error; IIV¼interindividual variability; IOV¼interoccasion variability; RV¼residual variability.
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Figure 2 Relationship between the total topotecan dose (mg) per
course and the area under the plasma concentration–time curve (AUC) of
total topotecan (upper graph) and topotecan lactone (lower graph) in
course 1 (solid marker) and 2 (open marker).
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Figure 3 Typical plasma concentration–time profiles of IF, 2DCE,
3DCE, 4OHIF, and IFM of a patient receiving a 1-h infusion of
1.2gm
 2day
 1 ifosfamide for 3 consecutive days with a 3-week interval.
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ldrop of the objective function of 1. Differences between courses 1
and 2 were better described with random variability in AUC50. The
high Hill coefficients (44) indicated a steep dose–response
relationship for both compounds. Adding 4OHIF exposure to the
model did not result in an improvement of goodness-of-fit of this
relationship. Various nested models were tested where the Hill
coefficients and AUC50’s of the active moieties were assumed
equal. None of the models achieved a successful description of the
additivity.
The relationships between the AUC for the lactone and total
topotecan and the percentage decrease in THR could also be
described by sigmoidal–Emax models (Figure 5). The relatively
high standard errors of the estimates indicated lack of goodness-
of-fit, probably due to a lack of information on either end of the
extremes of the curve. Estimates of AUC50 and the Hill coefficient
are also presented in Table 8. The RV and IIV were confounded
due to insufficient data for the lactone form topotecan–THR
relationship. Therefore, the RV could not be estimated.
Responses
In all, 34 patients were assessable for therapeutic activity. Of these,
22 patients demonstrated stable disease and nine progressive
disease during treatment. Partial responses were documented in
three heavily pretreated patients all with ovarian cancer, which was
the predominant primary tumour site (61%) in this study. One
partial responder was dosed at the recommended dose and the
other two at the two underlying three-daily dose levels.
Table 7 Pharmacokinetics of IF, 2DCE, 3DCE, 4OHIF, and IFM with their s.e., IIV, IOV, and RV
Ifosfamide Deactivated metabolites Activated metabolites
Estimate (7s.e.) IIV (%) IOV RV Estimate (7s.e.) IIV (%) RV Estimate (7s.e.) IIV (%) RV
CLinit (lh
 1) 3.5270.18 22 6% F
*
2DCE (l
 1) 0.0040670.00077 70 F
*
4OHIF (l
 1) 0.14770.013 43
VIFO (l) 32.371.0 14 — K2DCE (h
 1) 0.11870.021 27 K4OHIF (h
 1) 73.8 —
Kenz,out (h
 1) 0.013770.0012 20 — AUC2DCE (mmh) 0.86170.132 AUC4OHIF (mmh) 0.048270.0044
t1=2;enzðhÞ 50.6 PE 0% PE 23.0%
AUCIFO (mmh) 4.6770.27 AE (mm) 5.10 AE (mm) 0.274
PE 14.3% F
*
3DCE (l
 1) 0.0063370.00044 29 F
**
IFM (h
 1) 0.5670.36 —
AE (mm) 4.51 K3DCE (h
 1) 0.075270.0038 — KIFM (h
 1) 4.071.5 76
AUC3DCE (mmh) 2.0470.13 AUCIFM (mmh) 0.39970.089
PE 17.3% PE 10.7%
AE (mm) 3.22 AE (mm) 4.50
CLinit¼initial ifosfamide clearance; VIFO¼volume of distribution of central compartment of ifosfamide; Kenz,out¼first-order rate constant for enzyme degradation/inactivation;
t1/2,enz (h)¼induction half-life of the enzyme; AUC¼area under the plasma concentration–time curve during the first course; PE¼proportional error; AE¼additive error;
F
*¼ratio of fraction metabolised and volume of distribution of metabolite; K¼first-order rate constant for metabolite elimination; F
**¼formation rate constant; IF¼ifosfamide;
2DCE¼2-dechloroethylifosfamide; 3DCE¼3-dechloroethylifosfamide; 4OHIF¼4-hydroxyifosfamide; IFM¼ifosforamide mustard; s.e.¼standard error; IIV¼interindividual
variability; IOV¼interoccasion variability; RV¼residual variability.
0
20
40
60
80
100
0 200 400 600 800 1000
AUC total topotecan (nM . h)
%
 
d
e
c
r
e
a
s
e
 
i
n
 
A
N
C
 
a
t
 
N
A
D
I
R
%
 
d
e
c
r
e
a
s
e
 
i
n
 
A
N
C
 
a
t
 
N
A
D
I
R
Course 1
Course 2
Course 1
Course 2
0
20
40
60
80
100
0 100 200 300
AUC lactone topotecan (nM . h)
Figure 4 Percentage decrease in absolute neutrophil count (ANC) vs
the area under plasma concentration–time curve (AUC) of total (upper
graph) and lactone (lower graph) topotecan during course 1 (solid
markers) and course 2 (open markers). The line indicates the best fit of the
data to the sigmoidal–Emax model.
Table 8 Estimated parameters with their s.e. of the relationship between
the area under the plasma concentration–time curve (AUC) of lactone
and total topotecan and the percentage decrease in ANC and THRs in
courses 1 and 2 of 23 patients
Topotecan lactone Total topotecan
Estimate (7s.e.) IOV Estimate (7s.e.) IOV
Decrease in ANC
Emax (%) 100 fixed 100 fixed
AUC50 (mm) 10578 22% 263723 29%
g 4.5471.14 4.1170.66
AE 0.4% 0.1%
Decrease in thrombocytes
Emax (%) 100 fixed 100 fixed
AUC50 (mm) 131711 41% 376741 64%
g 1.7770.58 1.0970.36
AE — 8.9%
IOV¼interoccasion variability (random variability between courses 1 and 2);
Emax¼maximum effect; AUC50¼topotecan AUC associated with 50% of Emax;
g¼Hill coefficient; AE¼additive error; s.e.¼standard error; ANC¼absolute
neutrophil count; THR¼thrombocyte; AE¼additive error.
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There are few anticancer agents that have significant therapeutic
impact when used alone, particularly in the treatment of solid
tumours. The single-agent and combination therapy activities of
topotecan and IF have been extensively studied (Herben et al,
1996; Kerbusch et al, 2001a). Murren et al (1997) proposed a
synergistic cytotoxicity between topoisomerase-I inhibitors and
alkylating agents. Bioactivation of IF leads to the alkylating
compound IFM, which possesses a high affinity for macromole-
cules such as DNA. DNA alkylation leads to crosslink formation
finally resulting in cytotoxicity and cell death through apoptosis.
DNA alkylation initiates DNA repair mechanisms. Topoisomerase-
I may be involved in this machinery through unwinding of the
DNA. However, its direct relationship to the cytotoxic events of IF
is at present unclear. The suggested synergism encouraged us to
evaluate the feasibility and safety profile of the combination
topotecan with IF in cancer patients.
Haematological toxicity, especially neutropenia was the DLT for
this combination. Topotecan could not be safely administered in
the approved single agent (1.5mgm
 2) daily times five schedule.
Severe neutropenia and thrombocytopenia occurred at a dose of
0.6mgm
 2day
 1 for 5 days. To investigate further dose intensi-
fication, topotecan dosing was reduced from 5 to 3 days. With the
adjusted schedule, topotecan was escalated to 1.4mgm
 2day
 1.A t
that dose level DLT was observed. Additional patients at one dose
level below the highest also demonstrated unacceptable toxicity.
Therefore, the recommended dose was found to be
1.0mgm
 2day
 1 topotecan 3 days and 1.2gm
 2day
 1 IF 3
days. Seven patients were treated at the recommended dose with
acceptable toxicity.
The neutropenia was correlated with the dose intensity of
topotecan (Table 3), which was also observed in the previous
studies (van Warmerdam et al, 1995). Neutropenia is the most
frequently observed toxicity associated with single-agent topote-
can. In phase II trials of single-agent topotecan in adult patients
with solid tumours receiving 30-min infusions of 1.5–
2.0mgm
 2day
 1 for 5 days every 3 or 4 weeks, grade III–IV
neutropenia was observed in 71–75% of all courses (Creemers et al,
1995; Perez-Soler et al, 1996). The haematological toxicity was
generally of short duration, noncumulative, and manageable.
Ifosfamide’s principal toxicity is also haematological, albeit less
severe than of its isomer cyclophosphamide. A WBC count
o3 10
9l
 1 is expected in approximately 50% of patients and
platelet counts o100 10
9l
 1 in 20% of patients treated with
single-agent IF at a dose of 1.2gm
 2day
 1 for 5 days (Telekes and
Hendrich, 1996). Their overlapping toxicity profiles prevented
escalation of topotecan, in combination with IF, to a dose near the
single-agent MTD of 1.5mgm
 2day
 1 for 5 consecutive days.
Eight episodes (6%) of grade III anaemia were observed in all
courses, which were considered related to the study drugs. This is
in accordance with the observation that significant anaemia
occurred in 2–14% of all courses of phase II studies in patients
receiving single-agent topotecan at 1.5–2.0mgm
 2day
 1 for 5
days (Creemers et al, 1995; Perez-Soler et al, 1996).
Only four episodes (3%) of grade III thrombocytopenia were
observed in our study. Thrombocytopenia associated with single-
agent topotecan is rare and mainly reported after prolonged
infusion schedules (Herben et al, 1998). Severe thrombocytopenia
was observed in 2–10% of all courses in the above-mentioned
phase II studies of the daily 5 schedule (Creemers et al, 1995;
Perez-Soler et al, 1996).
Bone marrow G-CSF was not allowed in this study. Granulocyte
colony-stimulating factor could potentially improve the tolerance
to the combination regimen. However, preliminary results
presented by Bienvenu et al (2000) suggest the impact of G-CSF
to be limited. They recommended a dose of 1.0mgm
 2day
 1
topotecan in combination with 1.5gm
 2day
 1 IF, both daily for 3
consecutive days with G-CSF support from days 5 to 12.
Recently, Schneider et al (2002) published a study of this
combination therapy with G-CSF (when indicated) based on a 5-
day schedule. They observed pronounced nonhaematological
toxicity (hepatic and renal) and two treatment-related deaths out
of 11 patients. This is in contrast to our findings. No hepatic
toxicity, renal tubular abnormalities, or haemorrhagic cystitis were
observed. All nonhaematological toxicities were relatively mild,
not dose related, and transient with nausea, vomiting, fatigue,
constipation, and alopecia being the most observed. These have
been described before in phase II studies of single-agent topotecan
with similar incidence rates (Creemers et al, 1995). Peripheral
neuropathy or paresthesia has occurred rarely with topotecan
treatment and a causal relationship is uncertain. The relatively
high incidence of neuropathy in our study may be related to prior
treatment with paclitaxel in three and cisplatin in one of five
patients (Rowinsky et al, 1992). No encephalopathy, a specific IF-
related toxicity, was observed in this study (Cerny and Ku ¨pfer,
1992).
Population pharmacokinetic parameters of topotecan were
similar to previously reported parameter estimates obtained using
a population approach (Gallo et al, 2000) and a standard two-stage
analysis (Wall et al, 1992; van Warmerdam et al, 1995) after single-
agent administration of 0.5–2.0mgm
 2 topotecan in the daily
times five schedule. Gallo et al reported a CL of 32lh
 1 and
volume of distribution at steady state (Vss) of 120l, whereas the
current analysis found 29lh
 1 and 80l, respectively. This minor
discrepancy may be explained by differences in the characteristics
of the studied patients. Gallo et al identified weight, height serum
creatinine, and sex as significant covariates for CL and Vss. The
median values/frequency of these covariates were lower in the
current study resulting in lower estimates of CL and Vss. The CL of
the lactone (68lh
 1) form exceeded the total form (29lh
 1). This
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Figure 5 Percentage decrease in thrombocytes (THR) vs the area under
plasma concentration–time curve (AUC) of total (upper graph) and
lactone (lower graph) topotecan during course 1 (solid markers) and
course 2 (open markers). The line indicates the best fit of the data to the
sigmoidal–Emax model.
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lapparent CL of the lactone form is actually CL/F with F being the
fraction of the total concentration/amount of dose in lactone form.
Similar reasoning can be followed for V, Vss and Q. Metabolic
interactions of topotecan with concomitantly administered IF were
not anticipated, because topotecan metabolism to N-desmethylto-
potecan is only 0.4–3% of the dose (Herben et al, 1998).
Nephrotoxicity is frequently encountered with IF treatment.
Since approximately 40% of topotecan is eliminated by the
kidneys, IF-induced renal tubular damage could potentially alter
the renal CL of topotecan. In the current study, no episodes of
renal toxicity were observed. Creatinine CL, an indicator of renal
function, did not exceed reference values. In agreement with these
clinical findings, plasma profiles of topotecan on days 2 and 3 were
similar to those on day 1, which indicates that IF coadministration
at the applied dose regimen most likely did not interfere with
topotecan CL.
Population pharmacokinetic parameters of IF and metabolites
were similar to those reported in a previous pharmacokinetic study
using an identical model (Kerbusch et al, 2001b). In another study,
high doses of IF (9–12gm
 2) were administered as single agent by
a 72-h continuous infusion (Kerbusch et al, 2000b). A four-fold
higher value for t1/2,enz was obtained in the current study.
Furthermore, no IC50 could be estimated in the current study.
This may be explained by the fact that estimation of autoinduction
in a pharmacokinetic profile of a 1-h infusion is inherently
less feasible than in that of a 72-h continuous infusion of IF.
Although the combination was never administered in reverse
order, topotecan and IF did not appear to interact pharmacoki-
netically in the studied combination regimen, since the observed
pharmacokinetics were similar to those after single-agent admin-
istration.
The estimates for the parameters used to describe the
sigmoidal–Emax relationship of the pharmacokinetics and the
myelosuppression were similar to previously reported values. van
Warmerdam et al (1995) reported an AUC50 for total topotecan of
173nMh
 1 after single-agent topotecan (0.5–1.5mgm
 2day
 1
 5). In contrast, the Hill coefficients were two-fold higher than
previously reported (1.8), possibly indicating the additive effect of
IF on the myelosuppression. The relationship between the
topotecan exposure and the decrease in THR indicated that the
maximum decrease is not likely to be reached with the doses
studied. No structural differences (only random) were observed in
the estimates for the AUC50 in the first and second course. This
was in accordance with the observation that neutropenia was not
cumulative. So far, dose escalation of topotecan only reached
approximately 50% of the MTD of single-agent treatment with
topotecan. This indicated a considerable additive myelosuppres-
sive effect of IF. Exposure to the activated metabolites of IF (4OHIF
and IFM) ranged approximately five-fold in the study, although the
IF dose was not escalated. However, no clear relationship between
the exposure to these active metabolites and the myelosuppression
was observed (data not shown). Additive modelling of topotecan
lactone/total and 4OHIF did not result in an increased goodness-
of-fit of the relationship with myelosuppression. The inability to
detect this relationship can be explained by the limited number of
subjects, in which all data were available (n¼14) and the lack of
an IF dose escalation or myelosuppresion data after single-agent
topotecan or IF administration.
This phase I dose-escalating study was not designed for an
evaluation of efficacy. Nonetheless, 8% of the patients refractory to
standard therapy did demonstrate clinical benefit (partial
response) from this combination with dosing at and below the
recommended dose.
It was concluded that the combination treatment of topotecan
at 1.0mgm
 2day
 1 3 days with IF at 1.2gm
 2day
 1 3 days
was feasible. Possible clinical benefit and synergism of
this combination can only be evaluated in a phase II
trials. However, the combination schedule of topotecan and IF
did result in considerable haematological toxicity and in conjunc-
tion with previously reported pronounced nonhaematological
toxicities and treatment-related deaths, it may be concluded that
this is not a favourable combination. The combined tolerated dose
was lower than expected based on single-agent experiences. No
pharmacokinetic interaction could be detected. It is therefore
likely that the combination is characterised by overlapping
toxicity.
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